Company Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | James Caruso |
Contact Details
Address: 100 Campus Drive Florham Park, New Jersey 07932 United States | |
| Phone | 608 441 8120 |
| Website | cellectar.com |
Stock Details
| Ticker Symbol | CLRB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001279704 |
| CUSIP Number | 15117F500 |
| ISIN Number | US15117F8077 |
| Employer ID | 04-3321804 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James V. Caruso | President, Chief Executive Officer and Director |
| Chad J. Kolean CPA | Vice President, Chief Financial Officer and Secretary |
| Jarrod Longcor | Chief Operating Officer |
| Darrell Shane Lea | Chief Commercial Officer |
| Dr. Andrei Shustov M.D. | Senior Vice President of Medical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 10-Q | Quarterly Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 1, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 10-Q | Quarterly Report |